China Medical System Holdings Limited (SGX:8A8)

Singapore flag Singapore · Delayed Price · Currency is SGD
2.440
-0.090 (-3.56%)
Last updated: Feb 6, 2026, 9:00 AM SGT
Market Cap5.92B +106.7%
Revenue (ttm)1.40B +12.1%
Net Income293.38M +18.7%
EPS0.12 +20.1%
Shares Outn/a
PE Ratio20.19
Forward PE17.54
Dividend0.03 (1.15%)
Ex-Dividend DateSep 1, 2025
Volume20,000
Average Volume12,150
Open2.510
Previous Close2.530
Day's Range2.440 - 2.510
52-Week Range2.050 - 2.550
Betan/a
RSI55.14
Earnings DateMar 16, 2026

About SGX:8A8

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate ... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 6,095
Stock Exchange Singapore Exchange
Ticker Symbol 8A8
Full Company Profile

Financial Performance

In 2024, SGX:8A8's revenue was 7.47 billion, a decrease of -6.79% compared to the previous year's 8.01 billion. Earnings were 1.62 billion, a decrease of -32.54%.

Financial numbers in CNY Financial Statements